Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross Muken.
SAS, a provider of tools for data and health analysis, will supply the platform for a project sharing oncology data from studies by AstraZeneca, Janssen R&D, Pfizer and Sanofi.
A new report says the Japanese CRO market is seeing more growth as Japanese pharma firms, which traditionally kept research in-house, are now broadening their horizons to use more outsourcing partners.
Opko Health has agreed to acquire Inspiro Medical, an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules to treat respiratory diseases.
The British Generic Manufacturers Association (BGMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) will launch a forum for the generics industry to discuss manufacturing and quality issues.
Novartis has agreed to acquire GlaxoSmithKline’s oncology pipeline for as much as $16bn, while GSK will acquire Novartis’ vaccine business, excluding the flu vaccines, for as much as $7bn.
With Pfizer rumoured to be on the brink of a mega-merger with AstraZeneca, in-Pharmatechnologist.com brings you an interactive view of what £60bn ($101bn) could get.
RNA interference (RNAi) developers that saw stock prices fall after Novartis pulled out of the market last week have reiterated their belief in the therapeutic and revenue potential of gene silencing drugs.
As the European Medicines Agency (EMA) announces final consultations on its clinical trial data policy will begin at the start of May, we take a look at the issues surrounding trial transparency in Europe.
Biopharma executives believe there will be strong growth in domestic R&D activities and biopharma manufacturing, but fewer workers will be needed as efficiencies in productivity are achieved across the industry, according to a new survey from industry...
Swiss high potency active pharmaceutical ingredient (API) contractor Cerbios has broken ground on a building that will bring together its chemical and biological R&D departments.
Albemarle has agreed to sell its ibuprofen business to US chemical intermediates firm SI Group in a deal that will also see it divest the anaesthetic agent, propofol.
AMRI says its long-term outlook remains positive with continued demand for its contract research services despite plans to shutter a Discovery and Development Services facility.
Comments from Novartis, Eli Lilly and Pfizer revealed that industry is taking serious issue with some aspects of the draft guidance from the US FDA on social media and promotional materials online.
Consultancy and drug developer Certara has acquired specialty contract research organization (CRO) Synchrogenix Information Strategies, which offers regulatory writing and related services to biopharma and medical device companies worldwide.
Pharmaceutical clients view contract research organisations (CROs) with private equity investments as unstable and more focused on financial growth than their operations, according to Italian CRO Cromsource.
The amines market will grow 5% over the next decade according to BASF, which cited rising drugmaker demand as a key driver for its investment in a new German plant.
As larger partnerships between CROs and sponsors come to maturity, a new survey found that “a much greater proportion of CRO revenue growth” will come from small and medium-sized pharma and biotech sponsor deals.
Catalent will provide Hisun Pharmaceuticals with cell lines to help it develop infliximab, adalimumab and alemtuzumab biosimilars for the Chinese market.
Pfizer has reminded the creator of Viagra-flavoured ice cream that the blockbuster erectile dysfunction treatment should only be available on prescription.
Acura has reacquired the rights to its opioid abuse-deterrent technology from Pfizer and is looking for pharma partners to relaunch its oxycodone HCL drug Oxecta.
Industry group TransCelerate Biopharma has certified that training programs from CROs Icon and SynteractHCR meet minimum criteria for ICH’s good clinical practice (GCP) training.
US health insurer Independence Blue Cross (IBC) has selected LabCorp to be its preferred provider for outpatient and specialty lab services under a new eight year deal.
Hovione has obtained a US patent for a cheap capsule-based dry powder inhaler that it claims is cheaper for manufacturers to produce and easier for patients to use.
A recent study found that CRO employees are seeing rapid budget increases for salaries across the globe, with an average increase of about 4% for 2014.
Fake aspirin and anti-diarrhoeal medicines were amongst the largest counterfeit drugs haul discovered to be destined for the European Union, a French customs official says.
Inspecting the thousands of Chinese factories making APIs for the US market is a “hopeless task” even if the FDA gets the extra staff it wants according to a Congressional committee review.
Karyopharm Therapeutics has selected CRO Clinipace to help discover first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases,
Patient recruitment is “the major bottleneck” in clinical development, an Industry Standard Research report says, but though it predicts a drive to ‘push’ patients into trials, industry disagrees.
The Broad Institute in Massachusetts, US will provide computational modelling support for a joint research project between Pfizer and EMD Serono profiling the genomes of lupus patients.
Drugmakers in the EU making changes to their manufacturing processes will have to submit additional stability data, according to a new EMA (European Medicines Agency) guideline.
Much of the $91bn (€66bn) raised in biotech capital over the last twelve months will end up in the hands of the CRO industry, according to a survey from analyst firm Jeffries.
CMO Neuland Laboratories has opened a new manufacturing facility in Hyderabad, India as part of its collaboration with Tokyo-based API Corporation (APIC).
IPEC Americas has released a standardized letter and template that pharmaceutical companies can use to collect available information from their suppliers regarding elemental impurities in excipients.
Anticipated demand for the drug Exparel has led to a contract win for Patheon, though NDA holder Pacira says it will maintain control of all aspects of the manufacturing process.
Roche has clashed with the authors of a report slamming the efficacy of Tamiflu, each claiming the other’s analysis of patient data is seriously flawed.
Tamiflu shortens the duration of influenza symptoms by only half a day, does not stop person-to-person spread and increases the risk of nausea say the authors of a new review who want Governments to rethink stockpiling neuraminidase inhibitors.
Fungi have no place in an API facility, but soon enzymes derived from them may be commonplace say scientists developing oxidoreductases for cost and time saving industrial applications.
The National Institute for Health Research (NIHR) Clinical Research Network, which provides more than £284m ($475m) a year to support the delivery of clinical research studies, has reconfigured to become 15 local clinical research networks across England.
Genentech says its collaboration with PatientsLikeMe will enable more effective clinical trial recruitment but will not affect its partnerships with CROs.
